Jeremy Grantham Bristol Myers Squibb CO Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

$30.8 Billion
Q1 2025

A detailed history of Jeremy Grantham (Grantham, Mayo, Van Otterloo & Co. LLC) transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Grantham, Mayo, Van Otterloo & Co. LLC holds 173,396 shares of BMY stock, worth $8.34 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

173,396

Previous 21,020 724.91%

Holding current value

$8.34 Million

Previous $1.19 Million 790.15%

% of portfolio

0.03%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$53.9 - $63.11 $8.21 Million - $9.62 Million	152,376 Added 724.91%	173,396 $10.6 Million
Q4 2024 Feb 13, 2025	SELL	$51.92 - $59.94 $10.7 Million - $12.4 Million	-206,953 Reduced 90.78%	21,020 $1.19 Million
Q3 2024 Nov 13, 2024	SELL	$39.66 - $51.75 $10.8 Million - $14.1 Million	-272,273 Reduced 54.43%	227,973 $11.8 Million
Q2 2024 Aug 13, 2024	SELL	$40.25 - $52.99 $1.16 Million - $1.52 Million	-28,723 Reduced 5.43%	500,246 $20.8 Million
Q1 2024 May 14, 2024	SELL	$47.98 - $54.4 $3.19 Million - $3.61 Million	-66,388 Reduced 11.15%	528,969 $28.7 Million
Q4 2023 Feb 13, 2024	SELL	$48.48 - $57.85 $2.31 Million - $2.76 Million	-47,727 Reduced 7.42%	595,357 $30.5 Million
Q3 2023 Nov 13, 2023	BUY	$57.89 - $64.73 $981,409 - $1.1 Million	16,953 Added 2.71%	643,084 $37.3 Million
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $8.23 Million - $9.13 Million	129,122 Added 25.98%	626,131 $40 Million
Q1 2023 May 12, 2023	BUY	$65.71 - $74.53 $3.2 Million - $3.63 Million	48,700 Added 10.86%	497,009 $34.4 Million
Q4 2022 Feb 13, 2023	BUY	$68.48 - $81.09 $13.8 Million - $16.3 Million	201,622 Added 81.73%	448,309 $32.3 Million
Q3 2022 Nov 10, 2022	BUY	$0.13 - $76.84 $9,997 - $5.91 Million	76,900 Added 45.29%	246,687 $17.5 Million
Q2 2022 Aug 12, 2022	SELL	$72.62 - $79.98 $8.83 Million - $9.73 Million	-121,609 Reduced 41.73%	169,787 $13.1 Million
Q1 2022 May 13, 2022	SELL	$61.48 - $73.72 $23.8 Million - $28.6 Million	-387,763 Reduced 57.09%	291,396 $21.3 Million
Q4 2021 Feb 11, 2022	BUY	$53.63 - $62.52 $23.4 Million - $27.3 Million	436,675 Added 180.08%	679,159 $42.3 Million
Q3 2021 Nov 12, 2021	BUY	$59.17 - $69.31 $3.14 Million - $3.67 Million	52,993 Added 27.97%	242,484 $14.3 Million
Q2 2021 Aug 12, 2021	BUY	$61.91 - $67.42 $2.67 Million - $2.91 Million	43,100 Added 29.44%	189,491 $12.7 Million
Q1 2021 May 13, 2021	BUY	$59.34 - $66.74 $4.17 Million - $4.69 Million	70,300 Added 92.39%	146,391 $9.24 Million
Q4 2020 Feb 12, 2021	SELL	$57.74 - $65.43 $69,288 - $78,516	-1,200 Reduced 1.55%	76,091 $4.72 Million
Q2 2020 Aug 13, 2020	SELL	$54.82 - $64.09 $4.57 Million - $5.35 Million	-83,406 Reduced 51.9%	77,291 $4.55 Million
Q1 2020 May 14, 2020	BUY	$46.4 - $67.43 $2.84 Million - $4.13 Million	61,203 Added 61.51%	160,697 $8.96 Million
Q4 2019 Feb 13, 2020	SELL	$49.21 - $64.19 $820,429 - $1.07 Million	-16,672 Reduced 14.35%	99,494 $6.39 Million
Q3 2019 Nov 13, 2019	SELL	$42.77 - $50.71 $5.37 Million - $6.37 Million	-125,634 Reduced 51.96%	116,166 $5.89 Million
Q2 2019 Aug 13, 2019	BUY	$44.62 - $49.34 $789,774 - $873,318	17,700 Added 7.9%	241,800 $11 Million
Q1 2019 May 14, 2019	BUY	$45.12 - $53.8 $2.65 Million - $3.16 Million	58,800 Added 35.57%	224,100 $10.7 Million
Q4 2018 Feb 13, 2019	BUY	$48.76 - $63.23 $7.69 Million - $9.97 Million	157,700 Added 2075.0%	165,300 $8.59 Million
Q3 2018 Nov 14, 2018	SELL	$55.19 - $62.25 $171,089 - $192,975	-3,100 Reduced 28.97%	7,600 $472,000
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $641,358 - $699,244	10,700	10,700 $656,000

Others Institutions Holding BMY

# of Institutions

2,810

Shares Held

1.59B

Call Options Held

25.9M

Put Options Held

23.9M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $102B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track Jeremy Grantham's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.

Account